Former Indevus VP Agrees To Insider Trading Deal

By Nick Malinowski

Law360, New York (January 11, 2010, 6:05 PM ET) -- A former vice president of Indevus Pharmaceuticals Inc. has agreed to pay the U.S. Securities and Exchange Commission over $130,000 to settle insider trading allegations brought by regulators that accused the executive of dumping stock after he learned that approval of one of the biotechnology company's drugs was to be delayed.

Brooke Wagner, the former vice president of communications at Indevus, which was acquired by Endo Pharmaceuticals Inc. last year, neither admitted nor denied the allegations of the complaint in a consent judgment submitted by the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles